Showing 5331-5340 of 5956 results for "".
- ProQR Therapeutics Teams Up With Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker Program for People With Inherited Retinal Diseaseshttps://modernod.com/news/proqr-therapeutics-teams-up-with-foundation-fighting-blindness-and-blueprint-genetics-to-support-the-my-retina-tracker-program-for-people-with-inherited-retinal-diseases/2477280/ProQR Therapeutics, a company dedicated to changing lives through the creation of transformative RNA medicines for severe genetic rare diseases, announced its participation in the Foundation Fighting Blindness My Retina Tracker Program, a collaborative, open-access program run by Blueprint Geneti
- Staar Surgical Announces Strategic Cooperation Agreement with Senshinkai Eye Institute in Japanhttps://modernod.com/news/staar-surgical-announces-strategic-cooperation-agreement-with-senshinkai-eye-institute-in-japan/2477276/Staar Surgical announced that it entered a strategic cooperation agreement with Senshinkai Eye Institute (SEI), an eye care group with five locations in Japan. The agreement includes volume commitments for the company’s implantable collamer lenses (ICLs), ICL surgeon training and certification, t
- Verana Health Acquires PYA Analytics; Announces $100 Million Financinghttps://modernod.com/news/verana-health-acquires-pya-analytics-announces-100-million-financing/2477275/Verana Health announced that it has acquired the assets of data science company PYA Analytics (PYAA). Based in Knoxville, Tennessee, PYAA specializes in large-scale data architecture solutions. Terms of the deal were not disclosed. PYAA was founded in 2013 by scientists and engineer
- Acucela Meets with NASA and TRISH for Phase 1 Update for SS-OCT Projecthttps://modernod.com/news/acucela-meets-with-nasa-and-trish-for-phase-1-update-for-ss-oct-project/2477272/Acucela announced that the company was invited to meet with NASA and the Translational Research Institute for Space Health (TRISH)1 to present the status of its Swept Source-OCT (SS-OCT) device being developed for NASA’s Deep Space missions. The purpose of the meeting, which too
- ForwardVue Pharma CEO: “Short Path to the Clinic” for Retinal Disease Treatmenthttps://modernod.com/news/forwardvue-pharma-ceo-short-path-to-the-clinic-for-retinal-disease-treatment/2477263/In an interview with Proactive’s Christine Corrado at the Biotech Showcase 2020 in San Francisco, ForwardVue Pharmaceuticals CEO Alan Franklin, MD, PhD, who is an ophthalmologist, said the company’s lead molecule aims to treat retinal neovascular disease.
- Think About Your Eyes Launches Enhanced Websitehttps://modernod.com/news/think-about-your-eyes-launches-enhanced-website/2477258/Think About Your Eyes, a national public awareness campaign by The Vision Council and the American Optometric Association, announced the launch of its new website. Featuring new content and a modern, easy-to-navigate design, the new platform provides information on eye health, eye conditions, vis
- Potent affronEYE Saffron Extract May Lower Risk of Glaucomahttps://modernod.com/news/potent-affroneye-saffron-extract-may-lower-risk-of-glaucoma/2477259/A new animal study suggests affronEYE saffron could help prevent the onset of glaucoma. The antioxidant and anti-inflammatory characteristics of this potent saffron extract, developed by Pharmactive Biotech Products, S.L., demonstrated an ability to protect retinal cells from damage and death and
- USRetina Announces Changes to Senior Management Teamhttps://modernod.com/news/usretina-announces-changes-to-senior-management-team/2477256/USRetina, an independent provider of technology and services specific to retina practices, announced that it has expanded its leadership team with the appointment of a new executive team. The change reflects a strategic approach to long-term value and growth for the organization, according to the
- Ocuphire Pharma Announces In-License of Phase 2 Oral Small Molecule Drug Candidate for DR and DME from Apexian Pharmaceuticalshttps://modernod.com/news/ocuphire-pharma-announces-in-license-of-phase-2-oral-small-molecule-drug-candidate-for-dr-and-dme-from-apexian-pharmaceuticals/2477254/Ocuphire Pharma announced that it has entered into an agreement with Apexian Pharmaceuticals, granting Ocuphire an exclusive worldwide sublicense to Apexian’s Ref-1 Inhibitor program, including its lead drug candidate APX3330, for all ophthalmic and diabetic indications. APX3330 is a first
- Tangible Science Announces Timing for Tangible Boost Launchhttps://modernod.com/news/tangible-science-announces-timing-for-tangible-boost-launch/2477250/Tangible Science recapped its 2019 accomplishments and announced the expected launch timing for its new conditioning solution, Tangible Boost. In 2019, the company developed agreements and collaborated with SynergEyes, Contamac, Bausch+Lomb, Paragon Vision Sciences, and Acuity Polymers to